OBJ LIMITED

PRESS RELEASE

16 August 2005

FOR IMMEDIATE RELEASE

OBJ to present at the World Congress on Inflammation and the World Congress on Pain

OBJ Limited (OBJ) has been invited to present at the 7th World Congress on Inflammation in Melbourne in late August. This follows OBJ's invitation to present at the World Congress on Pain in Sydney in the same month.

Dr Chris Quirk and Mr Jeffrey Edwards will present the OBJ 'smart' drug-patch delivery system and the commercial opportunities resulting from the technology at the BioPartnership session of the 7th World Congress on Inflammation.

Recent independent University results achieved by OBJ's through-skin drug patch technology in the field of anaesthetics will be presented by Dr Heather Benson, for the first time to an international audience as a poster presentation at the 11th World Congress on Pain in Sydney.

These invitations follow the company's announcements that its Dermaportation smart drug-patch technology which was shown to increase the through-the-skin delivery of a range of commercially and medically important drugs including a 900% increase in the delivery of the anti-cancer drug 5-aminolevulinic acid, an increase of 600% in caffeine delivery and a reduction in the time taken to deliver local anaesthetics by 70%.

The company maintains an active and continuous technology development and drug testing program as a means of identifying commercially important opportunities for through-the-skin delivery of drugs, hormones and cosmetic compounds.

- END -

OBJ Limited (ACN 056 482 636)
Ground Floor, 284 Oxford Street, Leederville, Western Australia 6007
Phone: +61 8 9443 3011 Fax: +61 8 9443 3866 Email: jedwards@obj.com.au

OBJ LIMITED

PRESS RELEASE

Background to the Announcement

OBJ Limited is a drug delivery company, developing electronic "drug patch" technologies that allow drugs, therapeutic agents and cosmetic compounds to be delivered more effectively and more efficiently through-the-skin.

The company had previously announced a 600% increase in the rate of delivery of the drug caffeine and a 70% reduction in the delivery times for the anaesthetic drugs lignocaine and prilocaine hydrochloride. More recently, it had demonstrated precise control over drug delivery rates and recent finding added an additional time-based control mechanism previously not seen in the drug delivery sector.



OBJ maintains a continuous drug patch and drug delivery program that includes a number of commercially significant anti-inflammatory, anti-pain, anti-oxidant and anti-cancer drugs, as well as a number of cosmetic compounds.

Illustrated above is the OBJ 'smart' coin-sized drug patch system currently under development to improve the drug delivery and efficacy of a range of existing commercial drugs.

Sustainable Benefits

Through-the-skin delivery of drugs, hormones, vitamins, vaccines, anti-bodies and anti-aging molecules provides economic, safety and efficacy benefits to the pharmacology, medical, veterinary and cosmetic industries. Cost reductions are achieved through self administration, reduced administration costs and regulatory costs with a corresponding increase in safety and patient compliance.

Side effects may be reduced in many cases by localized delivery and programmed delivery rates. Needle stick injuries and needle disposable problems can be eliminated while the reduction in the level of skill required for application can significantly reduce total cost of administration.

Independence of Results

OBJ contracts its drug and technology testing programs to independent and respected organisations, such as Western Australian Biomedical Research Institute, Western Australian Institute for Medical Research, Curtin University of Technology and Murdoch University.

The high level of independence and international accreditation means that the results attributable to OBJ's proprietary technology can be published and presented at major medical and scientific conferences and forums.

For more information:
Jeffrey Edwards
Phone: +61 8 944 33011
Mobile: 041 791 2211
E-mail: jedwards@obj.com.au